Minocycline: Neuroprotective Mechanisms in Parkinsons Disease

Thomas, M.; Le, W.

doi:10.2174/1381612043453162

Cited by 114Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration MechanismsNuclear Receptors and Signaling

Minocycline: Neuroprotective Mechanisms in Parkinsons Disease

Thomas, M., Le, W.·2004·Current Pharmaceutical Design

DOI 10.2174/1381612043453162

Open this paper in CoChat — free account

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by cardinal features of tremor, bradykinesia, rigidity and postural instability. In addition to the motor symptoms patients experience cognitive decline eventually resulting in severe disability. Pathologically PD is characterized by neurodegeneration in the substantia nigra pars compacta (SNc) with intracytoplasmic inclusions known as Lewy bodies. In addition to the SNc there is neurodegeneration in other areas including cerebral cortex, raphe nuclei, locus ceruleus, nucleus basalis of meynert, cranial nerves and autonomic nervous system. Recent evidence supports the role of inflammation in Parkinson's disease. Apoptosis has been shown to be one of the pathways of cell death in PD. Minocycline, a tetracycline derivative is a caspase inhibitor, and also inhibits the inducible nitric oxide synthase which are important for apoptotic cell death. Furthermore, Minocycline has been shown to block microglial activation of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonism animal models and protect against nigrostriatal dopaminergic neurodegeneration. In this review, we present the current experimental evidence for the potential use of tetracycline derivative, minocycline, as a neuroprotective agent in PD.

Integrity signals

Registry

Crossref · 10.2174/1381612043453162

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Minocycline efficiently crosses the BBB.
“Thanks to the ability to efficiently cross the BBB, minocycline is considered neuroprotective for a variety of neurological conditions, including PD [251,252,253,254,255,256,257].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [256]
Minocycline is considered neuroprotective for a variety of neurological conditions, including PD.
“Thanks to the ability to efficiently cross the BBB, minocycline is considered neuroprotective for a variety of neurological conditions, including PD [251,252,253,254,255,256,257].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [256]

Sorted by citations

Inflammation in neurodegenerative diseases
Amor, S., Puentes, F., Baker, D., & Van Der Valk, P. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03225.x · Cited by 1,355 · see citing works
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935 · see citing works
“The potential efficacy of minocycline in the treatment of Parkinson’s, Alzheimer’s and Huntington’s diseases has been proposed.”
BackgroundInfluential
Mechanisms of noise-induced hearing loss indicate multiple methods of prevention
Prell, C. G. L., Yamashita, D., Minami, S., Yamasoba, T., & Miller, J. M. (2006) · Hearing Research · doi:10.1016/j.heares.2006.10.006 · Cited by 370 · see citing works
“…to play major roles in neurodegenerative diseases, such as Alzheimer’s disease (de la Monte et al., 2000;Gilgun-Sherki et al., 2003;Chong et al., 2004;Summers, 2004), Parkinson’s disease (Le and Frim, 2002;Tenenbaum et al., 2002;Thomas and Le, 2004), and traumatic brain injury (Lewen et al., 2000).”
Background
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285 · see citing works
“Besides antimicrobial effects, minocycline was shown to exert neuroprotective and antiinflammatory activity in preclinical studies in the MPTP model of PD (Du et al., 2001; Thomas and Le, 2004; Wu et al., 2002).”
Background
The mitochondrial death pathway: a promising therapeutic target in diseases
Gupta, S., Kass, G. E. N., Szegezdi, É., & Joseph, B. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00697.x · Cited by 278 · see citing works
“The semi-synthetic tetracycline antibiotic minocycline has been found in a large number of studies to provide protection from neurodegeneration and ischemic neuronal injury [338], CD95mediated hepatic injury [131] and hypoxic/ischemic renal and hepatic injury [310, 339].”
Background
Minocycline as a Neuroprotective Agent
Stirling, D. P., Koochesfahani, K. M., Steeves, J. D., & Tetzlaff, W. (2005) · The Neuroscientist · doi:10.1177/1073858405275175 · Cited by 280 · see citing works
Oxidative and Antioxidative Potential of Brain Microglial Cells
Dringen, R. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.1223 · Cited by 266 · see citing works
Inflamm-Aging, Cytokines and Aging: State of the Art, New Hypotheses on the Role of Mitochondria and New Perspectives from Systems Biology
Salvioli, S., Capri, M., Valensin, S., Tieri, P., Monti, D., Ottaviani, E., & Franceschi, C. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777947470 · Cited by 240 · see citing works
Anti-Inflammatory Targets for the Treatment of Reperfusion Injury in Stroke
Mizuma, A., & Yenari, M. A. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00467 · Cited by 226 · see citing works
Recent Advances in Methamphetamine Neurotoxicity Mechanisms and Its Molecular Pathophysiology
Yu, S., Zhu, L., Shen, Q., Bai, X., & Di, X. (2015) · Behavioural Neurology · doi:10.1155/2015/103969 · Cited by 176 · see citing works
Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine
Zhang, L., Kitaichi, K., Fujimoto, Y., Nakayama, H., Shimizu, E., Iyo, M., & Hashimoto, K. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.05.015 · Cited by 159 · see citing works
What is behind the non-antibiotic properties of minocycline?
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.006 · Cited by 158 · see citing works
“Of note, minocycline has also emerged among the etracycline derivatives as the most effective one regarding neurorotection [15], an effect confirmed in various experimental models f brain injury [16,17], as well as in several neurodegenerative onditions like Parkinson’s disease [18,19], Huntington’s disease 20,21], am…”
Background
Minocycline Confers Early but Transient Protection in the Immature Brain following Focal Cerebral Ischemia—Reperfusion
Fox, C. K., Dingman, A., Derugin, N., Wendland, M. F., Manabat, C., Ji, S., Ferriero, D. M., & Vexler, Z. S. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600121 · Cited by 157 · see citing works
“…of minocycline in experimental models of neurodegeneration have shown promising results (Arvin et al, 2002; Popovic et al, 2002; Teng et al, 2004; Thomas and Le, 2004; Thomas et al, 2003; Yrjanheikki et al, 1998, 1999; Zhu et al, 2002), while other studies show no protection (Diguet et al,…”
BackgroundResultInfluential
Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline
Casarejos, M. J., Menéndez, J., Solano, R. M., Rodríguez‐Navarro, J. A., de Yébenes, J. G., & Mena, M. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03777.x · Cited by 156 · see citing works
The Potential of Minocycline for Neuroprotection in Human Neurologic Disease
Zemke, D., & Majid, A. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000150867.98887.3e · Cited by 125 · see citing works
“Minocycline has been found to block the activation of microglia and protect against neurodegeneration in both the 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) models of Parkinson disease.(48) Minocycline has been found to be protective in the MPTP model of Parkinson disease when…”
Background
Doxycycline restrains glia and confers neuroprotection in a 6‐OHDA Parkinson model
Lazzarini, M., Martin, S., Mitkovski, M., Raisman‐Vozari, R., Stühmer, W., & Bel, E. D. (2013) · Glia · doi:10.1002/glia.22496 · Cited by 119 · see citing works
“The tetracycline-derivative doxycycline (a-6 deoxy5-hydroxytetracycline) has been shown to be neuroprotective in in vitro and in vivo models of neurodegenerative diseases (Du et al., 2001; Kim and Suh, 2009; Purisai et al., 2007; Thomas and Le, 2004; Wang et al., 2003).”
Background
Delayed neurotrophin treatment following deafness rescues spiral ganglion cells from death and promotes regrowth of auditory nerve peripheral processes: Effects of brain‐derived neurotrophic factor and fibroblast growth factor
Miller, J. M., Prell, C. G. L., Prieskorn, D. M., et al. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21320 · Cited by 109 · see citing works
Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture
Chan, W. S., Durairajan, S. S. K., Lu, J., Wang, Y., Xie, L., Kum, W.-F., Koo, I., Yung, K. K. L., & Li, M. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.04.012 · Cited by 107 · see citing works
Minocycline Attenuates Hyperlocomotion and Prepulse Inhibition Deficits in Mice after Administration of the NMDA Receptor Antagonist Dizocilpine
Zhang, L., Shirayama, Y., Iyo, M., & Hashimoto, K. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301313 · Cited by 105 · see citing works
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline
Fujita, Y., Ishima, T., Kunitachi, S., Hagiwara, H., Zhang, L., Iyo, M., & Hashimoto, K. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.031 · Cited by 99 · see citing works
“Accumulating evidence suggests that minocycline has potential therapeutic effects in several animal models of neurological diseases (Domercq and Matute, 2004; Yong et al., 2004; Thomas and Le, 2004; Stirling et al., 2005).”
Background
Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection
Zhou, H.-F., Liu, X., Niu, D.-B., Li, F., He, Q., & Wang, X.-M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.12.005 · Cited by 99 · see citing works
“Similarly, administration of iNOS inhibitors, peroxisome proliferator activated receptors-gamma (PPARg) inhibitors and cyclooxygenase 2 (COX-2) inhibitors also has been shown to confer neuroprotection against MPTP- and 6-OHDA-induced dopaminergic cell death in rodents (Barcia and Herrero Ezquerro, 2004; Barcia et al.,…”
Background
The Therapeutic Role of Minocycline in Parkinson’s Disease
Cankaya, S., Cankaya, B., Kilic, U., Kilic, E., & Yulug, B. (2019) · Drugs in Context · doi:10.7573/dic.212553 · Cited by 93 · see citing works
Involvement of pro- and antinociceptive factors in minocycline analgesia in rat neuropathic pain model
Rojewska, E., Popiołek-Barczyk, K., Jurga, A. M., Makuch, W., Przewłocka, B., & Mika, J. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.09.020 · Cited by 92 · see citing works
“Minocycline also has neuroprotective activity (Kim and Suh, 2009), as demonstrated in numerous neurodegenerative disease models in mice and rats (Du et al., 2001; Brundula et al., 2002; Nessler et al., 2002; Thomas and Le, 2004).”
Dopaminergic Enhancement of Cognitive Function
Mehta, M. A., & Riedel, W. J. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777698891 · Cited by 91 · see citing works
The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88 · see citing works
Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson’s disease
Rasheed, M. Z., Tabassum, H., & Parvez, S. (2016) · PROTOPLASMA · doi:10.1007/s00709-015-0930-2 · Cited by 79 · see citing works
“Minocycline also protects nigrostriatal dopaminergic neurodegeneration which is induced by 6-OHD and MPTP (Thomas and Le 2004).”
Background
Minocycline suppresses hypoxic activation of rodent microglia in culture
Suk, K. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.05.038 · Cited by 78 · see citing works
Treatment of postinfectious olfactory disorders with minocycline: A double‐blind, placebo‐controlled study
Reden, J., Herting, B., Lill, K., et al. (2011) · The Laryngoscope · doi:10.1002/lary.21401 · Cited by 73 · see citing works
Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain
Żychowska, M., Rojewska, E., Makuch, W., Luvisetto, S., Pavone, F., Marinelli, S., Przewłocka, B., & Mika, J. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.09.019 · Cited by 75 · see citing works
Chlortetracycline and Demeclocycline Inhibit Calpains and Protect Mouse Neurons against Glutamate Toxicity and Cerebral Ischemia
Jiang, S. X., Lertvorachon, J., Hou, S., Konishi, Y., Webster, J., Mealing, G. A. R., Brunette, E., Tauskela, J. S., & Preston, E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503113200 · Cited by 72 · see citing works
Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain
Zhang, L., Shirayama, Y., Shimizu, E., Iyo, M., & Hashimoto, K. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.05.047 · Cited by 71 · see citing works
Increases in β-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-κB pathway activation
Cai, Z., Zhao, Y., Yao, S., & Zhao, B. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70504-7 · Cited by 62 · see citing works
“Minocycline, a tetracycline derivative, is a potential neuroprotective agent that blocks inflammation, oxidative stress and apoptosis [35, 66].”
Background
The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties
Garrido‐Mesa, N., Camuesco, D., Arribas, B., Comalada, M., Bailón, E., Cueto-Sola, M., Utrilla, P., Nieto, A., Zarzuelo, A., Rodríguez‐Cabezas, M. E., et al. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.12.011 · Cited by 62 · see citing works
Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions
Fernández-Gómez, F.-J., Galindo, M. F., Gómez-Lázaro, M., González-García, C., Ceña, V., Aguirre, N., & Jordán, J. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.019 · Cited by 59 · see citing works
P38 mitogen-activated protein kinase and Parkinson’s disease
He, J., Zhong, W., Zhang, M., Zhang, R., & Hu, W. (2018) · Translational Neuroscience · doi:10.1515/tnsci-2018-0022 · Cited by 56 · see citing works
Beyond the lesion site: minocycline augments inflammation and anxiety-like behavior following SCI in rats through action on the gut microbiota
Schmidt, E. K. A., Raposo, P. J. F., Espin, A. T., Fenrich, K. K., & Fouad, K. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02123-0 · Cited by 53 · see citing works
Minocycline mitigates motor impairments and cortical neuronal loss induced by focal ischemia in rats chronically exposed to ethanol during adolescence
de Oliveira, G. B., Fontes-Júnior, E. A., de Carvalho, S., da Silva, J. B., Fernandes, L. M. P., Oliveira, M. C. S. P., Prediger, R. D., Gomes‐Leal, W., Lima, R. R., & Maia, C. D. S. F. (2014) · Brain Research · doi:10.1016/j.brainres.2014.03.005 · Cited by 52 · see citing works
A Novel Target of Action of Minocycline in NGF-Induced Neurite Outgrowth in PC12 Cells: Translation Initiation Factor eIF4AI
Hashimoto, K., & Ishima, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015430 · Cited by 50 · see citing works
Tetracycline and viruses: a possible treatment for COVID-19?
Mosquera-Sulbarán, J., & Hernández–Fonseca, H. (2020) · Archives of Virology · doi:10.1007/s00705-020-04860-8 · Cited by 47 · see citing works
A limited role for microglia in antibody mediated plaque clearance in APP mice
Garcı́a-Alloza, M., Ferrara, B. J., Dodwell, S. A., Hickey, G. A., Hyman, B. T., & Bacskai, B. J. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.07.019 · Cited by 46 · see citing works
Minocycline Reduces Spontaneous Hemorrhage in Mouse Models of Cerebral Amyloid Angiopathy
Yan, P., Zhu, A., Liao, F., Xiao, Q.-L., Kraft, A. W., Gonzales, E., Perez, R., Greenberg, S., Holtzman, D., & Lee, J.-M. (2015) · Stroke · doi:10.1161/strokeaha.115.008582 · Cited by 35 · see citing works
Profile of minocycline and its potential in the treatment of schizophrenia
Zhang, L., & Zhao, J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s64236 · Cited by 45 · see citing works
“Apoptosis is indirectly suppressed by minocycline by inhibition of proinflammatory cytokines and nitric oxide.(77) Moreover, minocycline has been shown to be an inhibitor of poly-(ADP-ribose), polymerase-1, and matrix metalloproteinases.”
The Role of Inflammation in Neurodegenerative Diseases: Parkinson’s Disease, Alzheimer’s Disease, and Multiple Sclerosis
Fołta, J., Rzepka, Z., & Wrześniok, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115177 · Cited by 47 · see citing works
“In addition, it prevents the loss of dopamine in the striatum and inhibits the migration of T lymphocytes, promoting the protection of nigrostriatal dopaminergic neurons [73–75].”
Analgesic effect of minocycline in rat model of inflammation-induced visceral pain
Kannampalli, P., Pochiraju, S., Bruckert, M., Shaker, R., Banerjee, B., & Sengupta, J. N. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.026 · Cited by 37 · see citing works
“Minocycline effectively crosses the blood-brain barrier (Aronson, 1980) and has a proven safety record in humans (Thomas and Le, 2004).”
Background
Interaction between cytokines and ammonia in the mitochondrial permeability transition in cultured astrocytes
Alvarez, V. M., Rao, K. V. R., Brahmbhatt, M., & Norenberg, M. D. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22708 · Cited by 38 · see citing works
Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)
Sturchio, A., Marsili, L., Vizcarra, J. A., Dwivedi, A. K., Kauffman, M. A., Duker, A. P., Lu, P., Pauciulo, M. W., Wissel, B. D., Hill, E. J., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.553635 · Cited by 39 · see citing works
“…anti-inflammatory, anti-oxidant Bcl-2, BDNF, NGF, GDNF Nrf2, NF-κB, GSSG/GSH, oxidation of PUFA, oxidative pattern, NMDA-induced neurotoxicity Minocycline (Thomas, 2004; Zemke and Majid, 2004) Anti-oxidant, anti-apoptotic, anti-inflammatory, enhancement of immune system IL10, PGE-2, Th-2…”
Minocycline Treatment Reverses Sound Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome
Lovelace, J. W., Ethell, I. M., Binder, D. K., & Razak, K. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00771 · Cited by 36 · see citing works
Recent advances in the management and understanding of macular degeneration
Bahadorani, S., & Singer, M. A. (2017) · F1000Research · doi:10.12688/f1000research.10998.1 · Cited by 36 · see citing works
Use of minocycline in viral infections.
Dutta, K., & Basu, A. (2011) · PubMed Central · Cited by 39 · see citing works
Inflammation in parkinson’s disease
Hald, A., van Beek, J., & Lotharius, J. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_12 · Cited by 37 · see citing works
An emerging role of cGMP in the treatment of schizophrenia: A review
Shim, S. S., Shuman, M. D., & Duncan, E. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.015 · Cited by 35 · see citing works
“Minocycline also enhances Bcl-2 level and suppresses caspase expression by blocking the release of cytokines and NO (Thomas and Le, 2004) and activating the PKG pathway downstream (Dean et al.”
Minocycline Markedly Reduces Acute Visceral Nociception via Inhibiting Neuronal ERK Phosphorylation
Cho, I., Lee, M. J., Jang, M., Gwak, N.-G., Lee, K. Y., & Jung, H. (2012) · Molecular Pain · doi:10.1186/1744-8069-8-13 · Cited by 34 · see citing works
“Background Minocycline is a second-generation tetracycline antibiotic derivative that effectively crosses the blood-brain barrier [1], and which has a proven safety record in humans [2].”
Background
The neuroprotective efficacy of α-crystallin against acute inflammation in mice
Masilamoni, J. G., Vignesh, S., Kirubagaran, R., Jesudason, E. P., & Rajadas, J. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.07.002 · Cited by 33 · see citing works
SK3 Channel Overexpression in Mice Causes Hippocampal Shrinkage Associated with Cognitive Impairments
Martin, S., Lazzarini, M., Dullin, C., Balakrishnan, S., Gomes, F. V., Ninković, M., Hady, A. E., Pardo, L. A., Stühmer, W., & Bel, E. A. D. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9680-6 · Cited by 32 · see citing works
Anti-inflammatory and antiviral effects of minocycline in enterovirus 71 infections
Liao, Y.-T., Wang, S.-M., & Chen, S. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109271 · Cited by 32 · see citing works
Minocycline modulates chemokine receptors but not interleukin‐10 mRNA expression in hypoxic‐ischemic neonatal rat brain
Kremlev, S. G., Roberts, R. L., & Palmer, C. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21380 · Cited by 32 · see citing works
Minocycline fails to protect cerebellar granular cell cultures against malonate-induced cell death
Fernández-Gómez, F.-J., Gómez-Lázaro, M., Pastor, M. D., Calvo, S., Aguirre, N., Galindo, M. F., & Jordán, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.019 · Cited by 32 · see citing works
“, 2004; Huntington Study Group, 2004), has prompted the use of minocycline in several clinical trials (Gordon et al., 2004; Thomas and Le, 2004).”
Minocycline Protects Dopaminergic Neurons Against Long-Term Rotenone Toxicity
Radad, K., Moldzio, R., & Rausch, W.-D. (2010) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100009690 · Cited by 30 · see citing works
Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinson’s Disease
van Vuuren, M. J., Nell, T. A., Carr, J. A., Kell, D. B., & Pretorius, E. (2020) · Biomolecules · doi:10.3390/biom11010030 · Cited by 31 · see citing works
Minocycline treatment increases resistance to oxidative stress and extends lifespan in Drosophila via FOXO
Lee, G. J., Lim, J. J., & Hyun, S. (2017) · Oncotarget · doi:10.18632/oncotarget.21224 · Cited by 28 · see citing works
Antibiotic Minocycline Prevents Respiratory Syncytial Virus Infection
Bawage, S. S., Tiwari, P. M., Pillai, S., Dennis, V. A., & Singh, S. R. (2019) · Viruses · doi:10.3390/v11080739 · Cited by 25 · see citing works
Current management of Parkinson′s disease
Salawu, F., Olokoba, A. B., & Danburam, A. (2010) · Annals of African Medicine · doi:10.4103/1596-3519.64743 · Cited by 22 · see citing works
World No Tobacco Day 2011: India's progress in implementing the framework convention on tobacco control.
Schwartz, R. L., Wipfli, H. L., & Samet, J. M. (2011) · PubMed Central · Cited by 22 · see citing works
Neuroprotection for Parkinson’s disease
LeWitt, P. A. (2006) · Springer eBooks · doi:10.1007/978-3-211-33328-0_13 · Cited by 20 · see citing works
Advances in Neuropathic Pain Research: Selected Intracellular Factors as Potential Targets for Multidirectional Analgesics
Ciapała, K., & Mika, J. (2023) · Pharmaceuticals · doi:10.3390/ph16111624 · Cited by 19 · see citing works
Established and emerging techniques for the study of microglia: visualization, depletion, and fate mapping
Bobotis, B. C., Halvorson, T., Carrier, M., & Tremblay, M. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1317125 · Cited by 21 · see citing works
“…neuroprotective agent in experimental models for several CNS disorders, such as brain ischemia (Yrjänheikki et al., 1998), brain injury (Sanchez Mejia et al., 2001), Parkinson’s disease (Du et al., 2001; Thomas and Le, 2004), Huntington disease (Chen et al., 2000) and AD (Choi et al., 2007).”
Background
Minocycline Increases the Activity of Superoxide Dismutase and Reduces the Concentration of Nitric Oxide, Hydrogen Peroxide and Mitochondrial Malondialdehyde in Manganese Treated Drosophila melanogaster
Mora, M., Bonilla, E., Medina-Leendertz, S., et al. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1309-z · Cited by 18 · see citing works
“protect against nigrostriatal dopaminergic neurodegeneration [36].”
Neuroprotective Properties of Minocycline Against Methylphenidate-Induced Neurodegeneration: Possible Role of CREB/BDNF and Akt/GSK3 Signaling Pathways in Rat Hippocampus
Motaghinejad, M., & Motevalian, M. (2022) · Neurotoxicity Research · doi:10.1007/s12640-021-00454-7 · Cited by 17 · see citing works
“2010; Thomas and Le 2004).”
Role of inflammation and cellular stress in brain injury and central nervous system diseases
Barone, F. C., & Kilgore, K. S. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.010 · Cited by 17 · see citing works
Minocycline promotes the generation of dendritic cells with regulatory properties
Kim, N., Park, C., Im, S., Kim, J.-W., Lee, J., Park, Y.-J., Song, S., & Lee, C. (2016) · Oncotarget · doi:10.18632/oncotarget.10810 · Cited by 16 · see citing works
“com/oncotarget neurodegenerative conditions such as Huntington’s disease [34], Parkinson’s disease [35,36], Alzheimer’s disease [37], and multiple sclerosis [38], it is considered the most potent among tetracycline derivatives in regard to neuroprotection [39].”
Background
μ-Opioid and N-methyl-D-aspartate receptors in the amygdala contribute to minocycline-induced potentiation of morphine analgesia in rats
Ghazvini, H., Rezayof, A., Ghasemzadeh, Z., & Zarrindast, M. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000126 · Cited by 13 · see citing works
“A neuroprotective property of minocycline has been reported in animal models of neurodegenerative disorders such as Alzheimer’s disease (Hunter et al., 2004), multiple sclerosis (Chen et al., 2011), and Parkinson’s disease (Thomas and Le, 2004).”
Background
Potential of Antibiotics for the Treatment and Management of Parkinson's Disease: An Overview
Yadav, N., Thakur, A. K., Shekhar, N., & ., A. (2021) · Current Drug Research Reviews · doi:10.2174/2589977513666210315095133 · Cited by 14 · see citing works
Minocycline treatment improves proteostasis during Drosophila aging via autophagy mediated by FOXO and Hsp70
Lim, J. J., & Hyun, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112803 · Cited by 13 · see citing works
Minocycline for the management of multiple sclerosis: repositioning potential, opportunities, and challenges
Chauhan, P., Kakkar, A. K., Singh, H., & Gautam, C. S. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1838276 · Cited by 13 · see citing works
Minocycline Inhibits Microglial Activation and Improves Visual Function in a Chronic Model of Age-Related Retinal Degeneration
Du, X., Byrne, E. M., Chen, M., & Xu, H. (2022) · Biomedicines · doi:10.3390/biomedicines10123222 · Cited by 12 · see citing works
“Minocycline is also reported to be neuroprotective (independent of its anti-inflammation role) [41].”
Background
Characterization of alkanoyl-10-O-minocyclines in micellar dispersions as potential agents for treatment of human neurodegenerative disorders
Stefano, A. D., Sozio, P., Iannitelli, A., et al. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.02.123 · Cited by 12 · see citing works
Intracerebroventricular administration of lupus serum induces microglia activation and leukocyte adhesion in the cerebromicrovasculature of mice
Wang, X., Li, Y., Wang, Y., Feng, Q., Yang, P., & Qin, L. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.576994 · Cited by 11 · see citing works
“Parkinson’s disease (Thomas and Le, 2004), and Alzheimer’s disease (Budni et al.”
Minocycline treatment suppresses juvenile development and growth by attenuating insulin/TOR signaling in Drosophila animal model
Yun, H. M., Noh, S., & Hyun, S. (2017) · Scientific Reports · doi:10.1038/srep44724 · Cited by 11 · see citing works
Correction: A Novel Target of Action of Minocycline in NGF-Induced Neurite Outgrowth in PC12 Cells: Translation Initiator Factor eIF4AI
Hashimoto, K., & Ishima, T. (2010) · PLoS ONE · doi:10.1371/annotation/afc0a9a2-01c0-4e58-8d69-e0ed4ff953fa · Cited by 9 · see citing works
Minocycline as a potential anxiolytic drug: systematic review and meta-analysis of evidence in murine models
Iglesias, L. P., Soares, N., Asth, L., Moreira, F. A., & de Aguiar, D. C. (2023) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000754 · Cited by 9 · see citing works
“Preclinical studies have demonstrated that min-ocycline acts as a neuroprotector in models of traumatic brain injury (Sanchez Mejia et al. , 2001), neuropathic pain (Raghavendra et al. , 2003), and Parkinson's disease (Du et al. , 2001; Thomas and Le, 2004).”
Background
“Good” and “Bad” Microglia in Parkinson’s Disease: An Understanding of Homeostatic Mechanisms in Immunomodulation
Tang, Y., & Le, W. (2014) · Springer eBooks · doi:10.1007/978-3-319-08046-8_4 · Cited by 9 · see citing works
“MPTP Indirect [ 43 – 55 , 65 ]”
Self-citation
Minocycline Acts as a Neuroprotective Agent Against Tramadol-Induced Neurodegeneration: Behavioral and Molecular Evidence
Gholami, M., Ghelichkhani, Z., Aghakhani, R., Klionsky, D. J., Motaghinejad, O., Motaghinejad, M., Koohi, M. K., & Hassan, J. (2024) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_10_24 · Cited by 8 · see citing works
Minocycline encapsulated chitosan nanoparticles for central antinociceptive activity
Nagpal, K., Singh, S. K., & Mishra, D. N. (2014) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2014.07.055 · Cited by 8 · see citing works
Hypothesized neuroprotective effect of minocycline against COVID-19-induced stroke and neurological dysfunction: possible role of matrix metalloprotease signaling pathway
Shahrivar, A. A., Khakpourian, Z., Majdi, F., Sobhani, S., Coleman‐Fuller, N., Gholami, M., & Motaghinejad, M. (2022) · Biologia · doi:10.1007/s11756-022-01162-z · Cited by 7 · see citing works
“2010; Thomas and Le 2004).”
Parkinson's disease: aetiology, diagnosis, and management.
Leung, H., & Mok, V. (2005) · PubMed · Cited by 7 · see citing works
Minocycline ameliorates d-galactose-induced memory deficits and loss of Arc/Arg3.1 expression
Xu, L., Fen, L., Li, W., Xu, J., Sun, X., Qin, L., Zhang, Q.-L., Yao, Y., Yu, Q.-K., & Liang, X. (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-4051-6 · Cited by 6 · see citing works
“As mentioned previously, minocycline has emerged as the most effective tetracycline derivative that exerts neuroprotective effects in many experimental models, including those of traumatic brain injury [19], ischemia [20], neuropathic pain [21], and multiple neurodegenerative disorders including Alzheimer’s disease [2…”
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Mammalian Models of Parkinson's Disease
Schneider, J. S., Anderson, D. W., & Decamp, E. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00008-7 · Cited by 5 · see citing works
Emerging Techniques for the Study of Microglia: Visualization, Depletion and Fate MappingPreprint
Bobotis, B. C., Halvorson, T., Carrier, M., & Tremblay, M. (2023) · Preprints.org · doi:10.20944/preprints202308.2190.v1 · Cited by 3 · see citing works
Efficacy of minocycline in substance use disorder: A systematic review of preclinical and clinical studies
Eshrati, S., Nikbakhtzadeh, M., Arezoomandan, R., & Fattahi, A. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.173982 · Cited by 3 · see citing works
Burn-induced distant organ injury in rats and the effect of minocycline
BAHADIR, E., Sancar, M., TARHAN, G. G., KOÇAK, E., BUDANCAMANAK, Z., Karaaslan, S., Demirci, E., Yüksel, M., Ercan, F., & Ali̇can, İ. (2017) · Marmara medical journal · doi:10.5472/marumj.370641 · Cited by 3 · see citing works
“Minocycline is a semi-synthetic second-generation tetracycline with anti-apoptotic, immunosuppressive and anti-inflammatory actions in various pathological states including acne vulgaris, periodontitis, rheumatoid arthritis, asthma, scleroderma, Parkinson’s disease and Huntington’s disease [7-10].”
Background
Caspases; Modulators of Apoptosis and Cytokine Maturation — Targets for Novel Therapies
Knight, M. J., & Hawkins, C. J. (2006) · Springer eBooks · doi:10.1007/0-387-23695-3_4 · Cited by 4 · see citing works
“Conflicting outcomes were reported regarding the efficacy of minocycline in animal models of neuronal disease including Huntington's Disease (Bonelli et al., 2003; Chen et al., 2000; Denovan-Wright et al., 2002; Diguet et al., 2003; Hersch et al., 2003; Lee et al., 2003; Smith et al., 2003; Thomas et al., 2003; Wang e…”
Background
Minocycline has no Effect on the Fibrinolytic Activity of Alteplase
Farooq, M. U., Zemke, D., & Majid, A. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e423 · Cited by 2 · see citing works
Minocycline as an Evidence-Based Adjunct Treatment in Schizophrenia
Kelly, D. L., & Wehring, H. J. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180413-01 · Cited by 1 · see citing works
Minocycline
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01089-1 · Cited by 1 · see citing works
Drug Repurposing in CNS and Clinical Trials: Recent Achievements and Perspectives Focusing on Epilepsy and Related Comorbidities
Parreira, G. M., de Oliveira, A. C. P., Guarnieri, L. D. O., & Vieira, R. P. (2024) · Frontiers in clinical drug research. CNS and neurological disorders · doi:10.2174/9789815179842124120007 · Cited by 1 · see citing works
Relationship between Microglial Activation and Dopaminergic Neuronal Loss in 6-OHDA-induced Parkinsonian Animal Model
Lee, J.-S., Lee, J., Cho, W. G., Yang, Y.-C., & Cho, B. (2013) · Korean Journal of Physical Anthropology · doi:10.11637/kjpa.2013.26.1.13 · Cited by 1 · see citing works
CASPASES; MODULATORS OF APOPTOSIS AND CYTOKINE MATURATION - TARGETS FOR NOVEL THERAPIES Chapter IV
Knight, M. J., & Hawkins, C. J. (2005)
Neuroinflammation modifying approaches in Parkinsons disease
Samur, D. N., & Özbey, G. (2018) · The Journal of Neurobehavioral Sciences · doi:10.5455/jnbs.1517915407
Contemporary Review of Olfactory Dysfunction in COVID-19
Jung, H.-J., & Lee, H. (2021) · Journal of rhinology · doi:10.18787/jr.2020.00346
Tetraciclinas: ¿Antibióticos de uso potencial en la COVID-19?
Mosquera-Sulbarán, J., Pedreáñez, A. B., Diana Callejas, M., et al. (2021) · Investigación Clínica · doi:10.22209/ic.v62s2a06

Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure
Barcia, C., Sánchez-Bahíllo, A., Fernández‐Villalba, E., Bautista‐Hernández, V., Poza, M., Fernández-Barreiro, A., Hirsch, É. C., & Herrero, M. T. (2004) · Glia · doi:10.1002/glia.20015 · Cited by 206 · see citing works
Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
Vila, M., Jackson-Lewis, V. R., Vukosavić, S., Djaldetti, R., Liberatore, G. T., Offen, D., Korsmeyer, S. J., & Przedborski, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633998 · Cited by 372 · see citing works
Neuroprotective and anti-inflammatory role of Tinospora cordifolia in MPTP induced parkinsonian mouse model
Singh, S. P. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460-c2-038
Neuroprotective effects of cytokines in a pesticide model of Parkinson's disease
Gandhi, A. (2009) · doi:10.22215/etd/2009-12806
Plant-Derived Natural Products Targeting Multiple Pathways as Potential Therapeutics in the Treatment of Parkinson’s Disease
Vijay, A., & Balakrishnan, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-0534-8_14

Authors: Thomas, M., & Le, W.
Affiliations: Baylor College of Medicine (US)
Houston Methodist (US)
Venue: Current Pharmaceutical Design
Publisher: Bentham Science Publishers Ltd.
Published: 2004-02-01
Volume: 10
Issue: 6
Pages: 679-686
ISSN: 1381-6128 (ISSN-L)
DOI: 10.2174/1381612043453162
OpenAlex: W2091324444
Cited by: 114
References: 0
Citations by year: 2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 14 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 6 · 2016: 6 · 2015: 5 · 2014: 7 · 2013: 3 · 2012: 2
FWCI: 6.51
Type: journal article
Language: en
Open access: closed
Locations: Current Pharmaceutical Design (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
National Institute of Neurological Disorders and Stroke (1R01 NS04367, R01NS040370, 1R01 NS40370)
Topics: Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
Keywords: minocycline, Parkinson's disease, neuroprotection, neuroinflammation, apoptosis, caspase inhibition, inducible nitric oxide synthase, microglial activation, dopaminergic neuron loss, substantia nigra pars compacta, Lewy bodies, 6-hydroxydopamine, MPTP, tetracycline derivatives
MeSH terms: Animals, Antiparkinson Agents, Clinical Trials as Topic, Humans, Minocycline, Mitochondria, Parkinson Disease, Apoptosis, Oxidative Stress, Neuroprotective Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Minocycline: Neuroprotective Mechanisms in Parkinsons Disease

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cited by

Related

Record

About these checks